fda approved semaglutide compound versions of GLP-1 drugs for weight loss halted by The FDA has received reports

Serious skin reactions: Severe rash with blisters and peeling skin, especially around the mouth, nose, eyes, or genitals

Medicines and Healthcare products Regulatory Agency GOV.UK

HEC-007 (Sunshine Lake Pharma) - peptide, Phase 1 initiated August 2025

Transparent labeling with specific milligram amounts for each ingredient is the minimum standard for a trustworthy supplement

GLP-1 medications provide significant heart protection by reducing inflammation, improving cholesterol profiles, and lowering the risk of heart failure and stroke

The FDA will not enforce FDCA provisions that typically prohibit compounding of essentially a copy of an approved drug until February 18, 2025, for 503A pharmacies and March 19, 2025, for 503B outsourcing facilities